ArticleFrontiers in immunology2025
Integrating proteomics and machine learning reveals characteristics and risks of lymph node-independent distant metastasis in colorectal cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Spatially Resolved Metabolomic Profiling Reveals Progression-Associated Metabolic Reprogramming in Colorectal Liver Metastasis.Metabolites · 2026Article
- CD45⁺ hybrid circulating cells may reflect tumor-immune interactions and serve as transcriptomic indicators of metastatic potential in prostate cancer.Theranostics · 2026Article
- Identify MTDH as a Key Gene of Radio-Resistance in Colorectal Cancer Based on Multi-Omics and Experimental Validation.Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metastatic colorectal cancer (mCRC) poses significant treatment challenges, especially liver metastasis (CRLM). A notable proportion of CRC has synchronous metastasis independent of lymph node metastasis (LNM). The biological traits of lymph node-independent metastasis in CRC are unclear, and early synchronous metastasis is hard to predict with current imaging or clinicopathological methods. Method: We collected samples from 12 CRC patients with synchronous distant metastasis without LNM (T1-3N0M1). Data-Independent Acquisition Mass Spectrometry (DIA-MS), multi-omics data integration, and machine learning were used to develop a Lymph node-Independent Metastasis Genes (LIMGs) signature to predict synchronous distant metastasis risk in stage I-II CRC patients and validate it in multi-cohort. Immune microenvironment across risk subgroups was calculated by Estimating Relative Subsets of RNA Transcripts (CIBERSORT). Tumor Mutation Burden (TMB), Microsatellite Instability (MSI) score, immune functions and immune checkpoint gene expression were analyzed to evaluate immunotherapy response. Single cell RNA sequencing (scRNA-seq) analysis illustrated the expression profile of integrin α11 (ITGA11) in CRC. Immunohistochemistry (IHC) confirmed its expression pattern, while wound healing and transwell assays elucidated the role of ITGA11 in CRC metastasis. Results: The LIMGs signature demonstrated strong predictive performance of lymph node-independent synchronous metastasis across cohorts. The high-risk subgroup exhibited enhanced extracellular matrix (ECM) remodeling, epithelial-mesenchymal transition (EMT) and correlated with immunosuppressive tumor microenvironment (TME), lower TMB and MSI score, indicating worse immunotherapy response. Additionally, machine learning reveal ITGA11's pivotal role in lymph node-independent metastasis. IHC scores showing significant discriminatory ability of ITGA11 across different samples. Wound healing and transwell assays reveal that the knockdown of ITGA11 hinders the migration and invasion of CRC SW480 cells. Conclusion: Our findings suggest that EMT-related signature LIMGs significantly affects lymph node-independent distant metastasis in CRC and effectively predicts non-LNM synchronous metastasis in stage I-II CRC patients. LIMG ITGA11 may promote early metastasis by enhancing migration and invasion. These offering insights into precise risk stratification and treatment for CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.